Takeda Pharmaceuticals’ poly ADP-ribose polymerase Inhibitor ‘Zejual (niraparib)’ has been granted marketing authorization in Korea in its tablet form.

The Ministry of Food and Drug Safety (MFDS) approved Zejula Tab 100 mg on the 31st.

Like its capsule formulation, Zejula Tab is indicated ▲as monotherapy for adult patients with ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) who have shown response (partial or complete response) to first-line platinum-based chemotherapy; ▲ as monotherapy for adult patients with platinum-sensitive recurrent high-grade serous ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) who have responded